Merck
FDA Approves Keytruda for Biliary Cancer, Rivals AstraZeneca’s Imfinzi
Merck’s Keytruda has received FDA approval to treat locally advanced unresectable or metastatic biliary tract cancer, alongside gemcitabine and cisplatin ...
Merck boosts revenue outlook on COVID-19 pill Lagevrio demand
In a surprising turn of events, Merck’s COVID-19 antiviral pill, Lagevrio, has defied expectations by generating an astounding $640 million ...
Padcev-Keytruda Combo Doubles Survival in First-Line Bladder Cancer Trial (ESMO 2023)
ESMO 2023: LBA6 Exciting results from the EV-302 phase 3 trial suggest that the partnership between Seagen and Astellas’ antibody-drug ...
Lagevrio, the first oral COVID-19 drug, to be available in US soon
As anticipated, the US government is in the process of phasing out its distribution of COVID-19 treatments. Merck & Co.’s ...
Merck’s antiviral pill Lagevrio may have triggered new COVID variants, study suggests
As concerns about the coronavirus continue to loom, the spotlight is once again on the most widely used oral antiviral ...
HHS says Merck can’t sue over Medicare drug price talks
Merck & Co., a prominent pharmaceutical company, led the charge in challenging the contentious Medicare price negotiation provisions outlined in ...
Setbacks Continue: Merck and Eisai’s Ambitious Combo of Keytruda-Lenvima Stumble in Head and Neck Cancer Battle
In a somber development for the pharmaceutical world, Merck and Eisai find themselves facing yet another roadblock on their quest ...
Merck’s Bold Bet: 6-Year Study on Oral PCSK9 Inhibitor Dominates Phase 3 Program
In the ever-evolving landscape of pharmaceutical breakthroughs, Merck & Co. has set its sights on a pioneering endeavor that could ...
Revolutionizing Biologics Manufacturing with $490M Partnership: Merck and Ginkgo Bioworks Join Forces
Source – Ginkgo Bioworks As part of this agreement, Ginkgo will contribute its expertise in cell engineering, ultra-high-throughput multiplexed screening, ...
Merck’s Ervebo has received US FDA approval for use in children 12 months of age and older
Source – Merck Merck announced that the US Food and Drug Administration (FDA) has granted expanded approval for Ervebo. The ...
Even after buying Prometheus for $10.8 billion, Merck is still looking for M&A opportunities
Earlier this year, Merck’s acquisition of Prometheus Biosciences for $10.8 billion provided the New Jersey company with a much-needed diversification ...
Merck’s V116 Vaccine Shows Positive Results in Phase III Trials
Source – Merck Merck, known as MSD outside of the United States and Canada, has announced highly encouraging initial results ...
Merck and Moderna Commence Phase III Study of V940 with KEYTRUDA for High-Risk Melanoma
Source – Merck Moderna and Merck announced the commencement of the pivotal Phase III randomized V940-001 clinical trial. This trial ...
Merck’s Gefapixant Receives Positive EU CHMP Opinion
Source – Merck MSD has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has ...
EU CHMP Grants Favorable Opinion to Merck’s Keytruda Combination for HER2-Positive Advanced Gastric Cancer
Source – Merck A new hope for patients with advanced gastric or GEJ cancer that is positive for both HER2 ...
CHMP Backs Approval of Pembrolizumab Combination Therapy for HER2+ Gastric Cancer in the EU
Source – Merck A new combination therapy for patients with advanced gastric or GEJ cancer that is positive for both ...
KEYNOTE-A18 Trial: Primary Endpoint – Progression-Free Survival in High-Risk Cervical Cancer
Source – Merck Merck has announced a groundbreaking development in its Phase III KEYNOTE-A18 trial, also referred to as ENGOT-cx11/GOG-3047. ...
Merck awards pandemic early warning system with a prize of €500,000
The annual Future Insight competition held by Germany’s Merck KGaA has awarded a €500,000 prize to Khalid Salaita, a professor ...
Merck increases its pressure on the IRA by requesting a ruling without a trial in its conflict with the US government
Merck is intensifying its fight against the drug price negotiation provisions in the Inflation Reduction Act (IRA) by requesting a ...
Merck’s Keytruda fails a study for early stomach cancer following metastatic disease victory
Source – Merck Inhibiting immune checkpoints hasn’t been very effective against stomach cancer. Merck has now added another failure to ...
Following Merck’s example, Bristol Myers Squibb has filed a lawsuit criticizing the IRA’s Medicare negotiations
Source – Bristol Myers Squibb Following Merck’s shocking lawsuit that contested several provisions of the Inflation Reduction Act (IRA), Bristol-Myers ...
Merck Completes Acquisition of Prometheus Biosciences, Expanding Pipeline with Potential Breakthrough Treatment
Source: Merck On June 16, 2023, Merck announced the successful completion of its acquisition of Prometheus Biosciences, making Prometheus a ...
Keytruda Triumphs: Promising Progression-Free Survival in HER2-Positive Gastric Cancer
Source: Merck Merck’s renowned cancer drug, Keytruda, may soon see an updated label for its effectiveness in treating HER2-positive stomach ...
Merck wins patent case for BRIDION in US District Court
Source- Merck On June 13, 2023 the US District Court for the District of New Jersey found in favor of ...
At EASL 2023, Merck will present data on the investigational GLP-1/glucagon receptor co-agonist Efinopegdutide (MK-6024) in patients with non-alcoholic fatty liver disease (NAFLD)
Source- Merck NJ-RAHWAY Efinopegdutide (MK-6024), an investigational GLP-1/glucagon receptor co-agonist, has new findings that have been accepted for oral presentation ...
